Nonalcoholic Fatty Liver Disease clinical trials
Showing 51–68 of 68 active trials. Describe your situation to see which ones look like a fit.
- Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk
- Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
- Isocaloric Navy-Bean Substitution in Adults With MASLD
- Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
- Liver Micro Flow - MRI
- Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
- Short and Long Term Clinical and Patient-Reported Outcomes Associated With Intragastric Balloon Placement in Patients With Nonalcoholic Fatty Liver Disease
- Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
- Optimal Measurement of Spleen Stiffness Among Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
- Guerbet Liver Fibrosis
- Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
- Physiologic and Functional Adaptations of Insulin Sensitive Tissues
- Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
- Evaluation of Miricorilant on Liver Fat in Patients With MASLD
- A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- AGED Diagnostics Liver Disease Assessment
- Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis
- Metabolic Pathology of Pediatric NAFLD
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.